BrainStorm Granted Key US Patent for Its Autologous Stem Cell Technology

March 24, 2014 10:31 AM

19 0

NEW YORK, NY and PETACH TIKVAH, ISRAEL, Mar 24, 2014 (Marketwired via COMTEX) -- BrainStorm Cell Therapeutics (otcqb:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology. The patent (No. 8,663,987) covers BrainStorm's proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.

The neurotrophic factors secreted by the company's patented cells include Glial Cell-Derived Neurotrophic Factor (GDNF) and Brain-Derived Neurotrophic Factor (BDNF), known to support the neural cell network by protection of existing motor neurons, promotion of motor neuron growth, and re-establishme...

Read more

To category page